Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats

被引:6
作者
Dalle Carbonare L. [1 ]
Bertoldo F. [1 ]
Valenti M.T. [1 ]
Zordan S. [2 ]
Sella S. [2 ]
Fassina A. [3 ]
Turco G. [3 ]
Realdi G. [2 ]
Lo Cascio V. [1 ]
Giannini S. [2 ]
机构
[1] Clinic of Internal Medicine D, Department of Biomedical and Surgical Sciences, University of Verona, 37134 Verona
[2] Medical Clinic I, Department of Medical and Surgical Sciences, University of Padua, Padua
[3] Section of Pathology, Department of Oncology and Surgical Sciences, University of Padua, Padua
关键词
Glucocorticoids; Histomorphometry; Microarchitecture; Rats; Risedronate; Secondary osteoporosis;
D O I
10.1007/BF03350811
中图分类号
学科分类号
摘要
Osteoporosis is a severe complication of glucocorticoid treatment. Bisphosphonates are a powerful therapeutic option to prevent osteoporotic fractures. The aims of this study were: a) to determine bone alterations induced by therapy with glucocorticoids (GC); b) to establish the efficacy of risedronate (Ris) in the prevention of these effects. We studied 40 female Sprague-Dawley rats randomly divided into 4 groups of treatment, administered 3 times a week sc: 1. Control: vehicle of methylprednisolone (GC) + vehicle of Ris; 2. Ris: Ris 5 μg/ kg body weight vehicle of GC; 3. GC: GC 7 mg/kg + vehicle of Ris; 4. GC+Ris: GC 7 mg/kg, Ris 5 μg/kg. Animals were treated for 30 days and then were sacrificed. Densitometry was performed at baseline and at the end of the treatment. Right tibiae were removed for histomorphometric analyses. The GC group showed a 7% decrease in bone density vs controls (p<0.05), while the GC+Ris group was associated with a 3.5% increase in bone density vs controls (p<0.05). In the GC group, histomorphometric evaluations showed reduced bone volume (BV/TV) and thinning of trabeculae (Tb.Th) vs controls (BV/TV: 31±1 vs 35±1%, p<0.05; Tb.Th: 43±2 vs 50±3 μm, p<0.01; Ac.f: 1.8±0.2 vs 1.6±0.3 N/yr). The GC+Ris group had increased BV/TV and Tb.Th, and reduced Ac.f vs the GC group. Ris also maintained trabecular microarchitecture. At the histological level, glucocorticoid-induced osteoporosis was characterized by decreased bone volume, reduced osteoblastic activity, and deterioration of microarchitecture. Ris counteracted these effects both by prolonging osteoblast activity, and by maintaining bone microarchitecture. © 2007, Editrice Kurtis.
引用
收藏
页码:739 / 746
页数:7
相关论文
共 50 条
[41]   Glucocorticoid-induced osteoporosis: Prevention and treatment [J].
Werth, VP .
REVUE DU RHUMATISME, 1997, 64 (06) :S84-S88
[42]   Glucocorticoid-Induced Osteoporosis: Update on Management [J].
Aprajita Jagpal ;
Kenneth G. Saag .
Current Treatment Options in Rheumatology, 2018, 4 (3) :279-287
[43]   Trends in prevention of glucocorticoid-induced osteoporosis [J].
Saag, Kenneth G. ;
Gehlbach, Stephen H. ;
Curtis, Jeffrey R. ;
Youket, Thomas E. ;
Worley, Karen ;
Lange, Jeffrey L. .
JOURNAL OF RHEUMATOLOGY, 2006, 33 (08) :1651-1657
[44]   Denosumab in the treatment of glucocorticoid-induced osteoporosis [J].
Ilke Coskun Benlidayi .
Rheumatology International, 2018, 38 :1975-1984
[45]   Treatment options for glucocorticoid-induced osteoporosis [J].
Chiodini, Iacopo ;
Merlotti, Daniela ;
Falchetti, Alberto ;
Gennari, Luigi .
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (06) :721-732
[46]   Advances in treatment of glucocorticoid-induced osteoporosis [J].
Hsu, Emory ;
Nanes, Mark .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2017, 24 (06) :411-417
[47]   Denosumab in the treatment of glucocorticoid-induced osteoporosis [J].
Benlidayi, Ilke Coskun .
RHEUMATOLOGY INTERNATIONAL, 2018, 38 (11) :1975-1984
[48]   Glucocorticoid-induced osteoporosis: Management update [J].
Adler R.A. .
Current Osteoporosis Reports, 2010, 8 (1) :10-14
[49]   Therapeutic patenting for glucocorticoid-induced osteoporosis [J].
Cooper, MS ;
Stewart, PM .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (06) :847-857
[50]   Bisphosphonates and glucocorticoid-induced osteoporosis: cons [J].
Lems, Willem F. ;
Saag, Kenneth .
ENDOCRINE, 2015, 49 (03) :628-634